Progress in reaching unvaccinated (zero-dose) children in India, 1992–2016: a multilevel, geospatial analysis of repeated cross-sectional surveys

Lancet Global Health
Dec 2021 Volume 9 Number 12 e1623-e1769
https://www.thelancet.com/journals/langlo/issue/current

 

Articles
Progress in reaching unvaccinated (zero-dose) children in India, 1992–2016: a multilevel, geospatial analysis of repeated cross-sectional surveys
Mira Johri, Sunil Rajpal, S V Subramanian
Summary
Background
Reaching zero-dose children (infants who receive no routine vaccinations) is a global strategic priority. We studied zero-dose children in India over 24 years to clarify aggregate trends and the contribution of large-scale social, economic, and geographical inequalities to these.
Methods
We did a multilevel, geospatial analysis of repeated cross-sectional surveys of all four rounds (1992–2016) of India’s National Family Health Survey to study the prevalence, distribution, and drivers of zero-dose (no first dose of diphtheria, tetanus, and pertussis) vaccination status. We included all children born to participating women who were aged 12–23 months at the time of the survey, as this is the standard age at which immunisation data are assessed. Children who died before the survey and those missing data on key outcomes or correlates were excluded. The outcome was child zero-dose vaccination status. We also compared the prevalence of nutritional deficits among zero-dose versus vaccinated children. For the most recent survey, we produced geospatial estimates identifying the prevalence of zero-dose children across states and districts and used these to project head count.
Findings
We examined 393 167 children for eligibility. 72 848 children were included in the final analytic data set. The proportion of zero-dose children in India declined from 33·4% (95% CI 32·5–34·2) in 1992 to 10·1% (9·8–10·4) in 2016. Progress notwithstanding, in 2016, zero-dose children remained concentrated among disadvantaged groups (prevalence in the bottom wealth quintile 15·3%, 95% CI 14·6–16·0; prevalence among mothers with no education 16·8%, 16·1–17·4). Compared with vaccinated children, zero-dose children were more likely to suffer from malnutrition in all survey rounds (prevalence of severe stunting in 1992: zero dose 41·3%, 95% CI 39·2–43·8 vs vaccinated 28·5%, 27·2–29·7; 2016: zero dose 24·9%, 23·6–26·2 vs vaccinated 18·7%, 18·3–19·1). In 2016, there were an estimated 2·88 (95% CI 2·86–2·89) million zero-dose children in India, concentrated in less developed states and districts and several urban areas.
Interpretation
Over a 24-year period in India, child zero-dose status was shaped by large-scale social inequalities and remained a consistent marker of generalised vulnerability. Interventions that address this cycle of intergenerational inequities should be prioritised.

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
Bihua Han, et al.

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
Shipo Wu, et al.

Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial
Paul R Chapman, et al.

Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Review
Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review
Anna Deal, et al. in collaboration with the European Society of Clinical Microbiology and Infectious Diseases Study Group for Infections in Travellers and Migrants (ESGITM)

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

Lancet Respiratory Medicine
Dec 2021 Volume 9 Number 12 p1343-1478, e110-e122
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
Szu-Min Hsieh, et al.

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study

Lancet Respiratory Medicine
Dec 2021 Volume 9 Number 12 p1343-1478, e110-e122
https://www.thelancet.com/journals/lanres/issue/current

 

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
Utkarsh Agrawal, et al.

The biological and clinical significance of emerging SARS-CoV-2 variants

Nature Reviews Genetics
Volume 22 Issue 12, December 2021
https://www.nature.com/nrg/volumes/22/issues/12

 

Review Article | 17 September 2021
The biological and clinical significance of emerging SARS-CoV-2 variants
In this Review, the authors describe our latest understanding of the emergence and properties of SARS-CoV-2 genetic variants, particularly those designated as WHO (World Health Organization) ‘variants of concern’. They focus on the consequences of these variants for antibody-mediated virus neutralization, with important implications for reinfection risk and for vaccine effectiveness.
Kaiming Tao, Philip L. Tzou, Robert W. Shafer

Lessons from vaccine-induced immune thrombotic thrombocytopenia

Nature Reviews Immunology
Volume 21 Issue 12, December 2021
https://www.nature.com/nri/volumes/21/issues/12

 

Comment | 18 October 2021
Lessons from vaccine-induced immune thrombotic thrombocytopenia
Here, John Kelton and colleagues provide an overview of vaccine-induced immune thrombotic thrombocytopenia (VITT), a very rare complication that has been observed following vaccination with adenoviral vector-based COVID-19 vaccines.
John Greenhow Kelton, Donald Mitchell Arnold, Ishac Nazy

The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?

Nature Reviews Immunology
Volume 21 Issue 12, December 2021
https://www.nature.com/nri/volumes/21/issues/12

 

Progress | 19 October 2021
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?
Individuals with asymptomatic COVID-19 can transmit the virus and may be at risk of long-term disease. In this Progress article, Boyton and Altman present current insights into immune responses in asymptomatic SARS-CoV-2 infection and discuss the relevance of asymptomatic disease for public health strategies.
Rosemary J. Boyton, Daniel M. Altmann

Using cross-species vaccination approaches to counter emerging infectious diseases

Nature Reviews Immunology
Volume 21 Issue 12, December 2021
https://www.nature.com/nri/volumes/21/issues/12

 

Perspective | 17 June 2021
Using cross-species vaccination approaches to counter emerging infectious diseases
Emerging diseases that affect humans often arise due to the crossover of infectious agents from animal reservoirs. In this Perspective, George Warimwe and colleagues discuss the concept of ‘One Health vaccinology’, an approach that aims to use key lessons from human and veterinary immunology to develop more effective vaccination strategies for emerging infectious diseases.
George M. Warimwe, Michael J. Francis, Bryan Charleston

Lessons from the elimination of poliomyelitis in Africa

Nature Reviews Immunology
Volume 21 Issue 12, December 2021
https://www.nature.com/nri/volumes/21/issues/12

 

Perspective | 25 October 2021
Lessons from the elimination of poliomyelitis in Africa
This Perspective chronicles the journey to the elimination of transmission of wild poliovirus in Africa, with a critical discussion of the global, continental, national and community actions that were required and the lessons learnt along the way.
Abdulaziz Mohammed, Oyewale Tomori, John N. Nkengasong

Engineering living therapeutics with synthetic biology

Nature Reviews Drug Discovery
Volume 20 Issue 12, December 2021
https://www.nature.com/nrd/volumes/20/issues/12

 

Review Article | 06 October 2021
Engineering living therapeutics with synthetic biology
The design of cell-based therapeutics with synthetic biology is a rapidly growing strategy in medicine for the development of effective treatments for a variety of diseases. This article discusses advances in synthetic biology approaches to programme living cells with therapeutic functions as well as challenges for their development.
Andres Cubillos-Ruiz, Tingxi Guo, Jose M. Lora

Will Africans take COVID-19 vaccination?

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

Research Article
Will Africans take COVID-19 vaccination?
AbdulAzeez A. Anjorin, Ismail A. Odetokun, Ajibola I. Abioye, Hager Elnadi, Mfon Valencia Umoren, Bamu F. Damaris, Joseph Eyedo, Haruna I. Umar, Jean B. Nyandwi, Mena M. Abdalla, Sodiq O. Tijani, Kwame S. Awiagah, Gbolahan A. Idowu, Sifeuh N. Achille Fabrice, Aala M. O. Maisara, Youssef Razouqi, Zuhal E. Mhgoob, Salim Parker, Osaretin E. Asowata, Ismail O. Adesanya, Maureen A. Obara, Shameem Jaumdally, Gatera F. Kitema, Taofik A. Okuneye, Kennedy M. Mbanzulu, Hajj Daitoni, Ezekiel F. Hallie, Rasha Mosbah, Folorunso O. Fasina
Research Article | published 01 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260575

Peer- and community-led responses to HIV: A scoping review

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

Peer- and community-led responses to HIV: A scoping review
George Ayala, Laurel Sprague, L. Leigh-Ann van der Merwe, Ruth Morgan Thomas, Judy Chang, Sonya Arreola, Sara L. M. Davis, Aditia Taslim, Keith Mienies, Alessandra Nilo, Lillian Mworeko, Felicita Hikuam, Carlos Garcia de Leon Moreno, José Antonio Izazola-Licea
Research Article | published 01 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260555

To vaccinate or not to vaccinate!? Predictors of willingness to receive Covid-19 vaccination in Europe, the U.S., and China

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

To vaccinate or not to vaccinate!? Predictors of willingness to receive Covid-19 vaccination in Europe, the U.S., and China
Julia Brailovskaia, Silvia Schneider, Jürgen Margraf
Research Article | published 01 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260230

Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system
George N. Ioannou, Pamela Green, Emily R. Locke, Kristin Berry
Research Article | published 01 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0259696

Psychological predictors of vaccination intentions among U.S. undergraduates and online panel workers during the 2020 COVID-19 pandemic

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

Psychological predictors of vaccination intentions among U.S. undergraduates and online panel workers during the 2020 COVID-19 pandemic
Suryaa Gupta, Shoko Watanabe, Sean M. Laurent
Research Article | published 30 Nov 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260380

COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation
Mazin Barry, Mohamad-Hani Temsah, Abdullah Alhuzaimi, Nurah Alamro, Ayman Al-Eyadhy, Fadi Aljamaan, Basema Saddik, Ali Alhaboob, Fahad Alsohime, Khalid Alhasan, Abdulkarim Alrabiaah, Ali Alaraj, Rabih Halwani, Amr Jamal, Sarah Alsubaie, Fatimah S. Al-Shahrani, Ziad A. Memish, Jaffar A. Al-Tawfiq
Research Article | published 29 Nov 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0244415

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 4 Dec 2021]

 

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
Chris Davis, Nicola Logan, Grace Tyson, Richard Orton, William T. Harvey, Jonathan S. Perkins, Guy Mollett, Rachel M. Blacow, The COVID-19 Genomics UK (COG-UK) Consortium , Thomas P. Peacock, Wendy S. Barclay, Peter Cherepanov, Massimo Palmarini, Pablo R. Murcia, Arvind H. Patel, David L. Robertson, John Haughney, Emma C. Thomson, Brian J. Willett, on behalf of the COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators
Research Article | published 02 Dec 2021 PLOS Pathogens
https://doi.org/10.1371/journal.ppat.1010022

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 4 Dec 2021]

 

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
Stephanie Fischinger, Deniz Cizmeci, Davy Deng, Shannon P. Grant, Nicole Frahm, Julie McElrath, Jonathan Fuchs, Pierre-Alexandre Bart, Giuseppe Pantaleo, Michael Keefer, William O. Hahn, Nadine Rouphael, Gavin Churchyard, Zoe Moodie, Yeycy Donastorg, Hendrik Streeck, Galit Alter
Research Article | published 29 Nov 2021 PLOS Pathogens
https://doi.org/10.1371/journal.ppat.1010016

Opinion: Toward inclusive global governance of human genome editing

PNAS – Proceedings of the National Academy of Sciences of the United States
November 23, 2021; vol. 118 no. 47
https://www.pnas.org/content/118/47

 

Front Matter
Opinion: Toward inclusive global governance of human genome editing
Hanzhi Yu, Lan Xue, Rodolphe Barrangou, Shaowei Chen, and Ying Huang
PNAS November 23, 2021 118 (47) e2118540118
https://doi.org/10.1073/pnas.2118540118

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Science
Volume 374| Issue 6572| 3 Dec 2021
https://www.science.org/toc/science/current

 

Research Articles
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
BY Rishi R. Goel, et al.
03 Dec 2021
Open Access
Blood analysis of individuals vaccinated with the Moderna SARS-CoV-2 mRNA vaccine reveals distinct trajectories of immune memory responses.

Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic

Travel Medicine and Infectious Diseases
Volume 44 November–December 2021
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C

 

Editorial Full text access
Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic
Alfonso J. Rodríguez-Morales, D. Katterine Bonilla-Aldana, José Antonio Suárez, Carlos Franco-Paredes, … Alberto Paniz-Mondolfi
Article 102192

Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes

Travel Medicine and Infectious Diseases
Volume 44 November–December 2021
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C

 

Research article Full text access
Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes
Clotilde El Guerche-Séblain, Lina Chakir, Gopinath Nageshwaran, Rebecca C. Harris, … Philippe Vanhems
Article 102171

A novel semi-quantitative methodology for national poliovirus reintroduction and outbreak risk assessment

Travel Medicine and Infectious Diseases
Volume 44 November–December 2021
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C

 

Research article Open access
A novel semi-quantitative methodology for national poliovirus reintroduction and outbreak risk assessment
Hendrik S. Camphor, Christina Bareja, Anna Glynn-Robinson, Benjamin G. Polkinghorne, David N. Durrheim
Article 102181

Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Discussion Full text access
Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future
Divya Hosangadi, Elena K. Martin, Matthew Watson, Richard Bruns, Nancy Connell
Pages 6972-6974

Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Abstract only
Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020
Sara Sanz-Rojo, Rodrigo Jiménez-García, Ana López-de-Andrés, Javier de Miguel-Diez, … José J. Zamorano-León
Pages 7012-7020

COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Full text access
COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study
Helena C. Maltezou, Periklis Panagopoulos, Flora Sourri, Theodoros V. Giannouchos, … Dimitrios Hatzigeorgiou
Pages 7021-7027

Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Full text access
Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study
Titilope Olanipekun, Temidayo Abe, Valery Effoe, Gloria Westney, Richard Snyder
Pages 7074-7081

Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Open access
Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study
Maria Esterlita T. Villanueva-Uy, Hilton Y. Lam, Josephine G. Aldaba, Tristan Marvin Z. Uy, … Clint Pecenka
Pages 7091-7100

Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch)

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Open access
Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch)
Thomas Byrne, Parth Patel, Madhumita Shrotri, Sarah Beale, … Richard Gilson
Pages 7108-7116

Pre-Print Servers

Pre-Print Servers

 

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 4 Dec 2021]

No new digest content identified.

 

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…
[Accessed 4 Dec 2021]
Selected Content
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Francisco Hernandez-Bernal, Maria del Carmen Ricardo-Cobas, Yenima Martin-Bauta, Zadis Navarro-Rodriguez, Marjoris Pinera-Martinez, Joel Quintana-Guerra, Karen Urrutia-Perez, Klaudia Urrutia-Perez, Cristina Olimpia Chavez-Chong, Jorge Luis Azor-Hernandez, Jose Luis Rodriguez-Reinoso, Leonardo Lobaina-Lambert, Elizabeth Colina-Avila, Jacqueline Bizet-Almeida, Jeniffer Rodriguez-Nuviola, Sergio del Valle-Pinera, Mayara Ramirez-Dominguez, Elisangela Tablada-Ferreiro, Marel Alonso-Valdes, Gilda Lemos-Perez, Gerardo Enrique Guillen-Nieto, Ariel Palenzuela-Diaz, Enrique Noa-Romero, Miladys Limonta-Fernandez, Juan Manuel Fernandez-Avila, Nabil Ali-Mros, Lianne del Toro-Lahera, Rossana Remedios-Reyes, Marta Ayala-Avila, Verena Lucila Muzio-Gonzalez
medRxiv 2021.11.30.21267047; doi: https://doi.org/10.1101/2021.11.30.21267047 Revision

Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders
Douglas Lake, Alexa J Roeder, Maria J Gonzalez-Moa, Megan Koehler, Erin Kaleta, Paniz Jasbi, John Vanderhoof, Davis Mckechnie, Jack Forman, Baylee Edwards, Alim Seit-Nebi, Sergei Svarovsky
medRxiv 2021.11.30.21266716; doi: https://doi.org/10.1101/2021.11.30.21266716

The Politics of Vaccine Hesitancy in the United States
Jian Cao, Christina Ramirez, R. Michael Alvarez
medRxiv 2021.12.01.21267160; doi: https://doi.org/10.1101/2021.12.01.21267160

Evaluating COVID-19 booster vaccination strategies in a partially vaccinated population: a modeling study.
Clement R Massonnaud, Jonathan Roux, Vittoria Colizza, Pascal Crepey
medRxiv 2021.12.01.21267122; doi: https://doi.org/10.1101/2021.12.01.21267122

Changes Over Time in COVID-19 Vaccination Inequalities in Eight Large U.S. Cities
S. Michael Gaddis, Colleen M. Carey, Nicholas V DiRago
medRxiv 2021.12.01.21267158; doi: https://doi.org/10.1101/2021.12.01.21267158

Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications
Andrew T Levin, Nana Owusu-Boaitey, Sierra Pugh, Bailey K Fosdick, Anthony B. Zwi, Anup Malani, Satej Soman, Lonni Besançon, Ilya Kashnitsky, Sachin Ganesh, Aloysius McLaughlin, Gayeong Song, Rine Uhm, Gideon Meyerowitz-Katz
medRxiv 2021.09.29.21264325; doi: https://doi.org/10.1101/2021.09.29.21264325

Convalescent plasma for outpatients with early COVID-19
Pere Millat-Martinez, Arvind Gharbharan, Andrea Alemany, Casper Rokx, Corine GeurtsvanKessel, Grigorios Papageourgiou, Nan van Geloven, Carlijn Jordans, Geert Groeneveld, Francis Swaneveld, Ellen van der Schoot, Marc Corbacho-Monne, Dan Ouchi, Francini Piccolo Ferreira, Pierre Malchair, Sebastian Videla, Vanesa Garcia Garcia, Anna Ruiz-Comellas, Anna Ramirez-Morros, Joana Rodriguez Codina, Rosa Amado Simon, Joan-Ramon Grifols, Julia Blanco, Ignacio Blanco, Jordi Ara, Quique Bassat, Bonaventura Clotet, Barbara Baro, Andrea Troxel, Jaap Jan Zwaginga, Oriol Mitja, Bart Rijnders
medRxiv 2021.11.30.21266810; doi: https://doi.org/10.1101/2021.11.30.21266810

Google Trends as a predictive tool for COVID-19 vaccinations in Italy: a retrospective infodemiological analysis
Alessandro Rovetta
medRxiv 2021.11.29.21267012; doi: https://doi.org/10.1101/2021.11.29.21267012

The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
Nasikarn Angkasekwinai, Suvimol Niyomnaitham, Jaturong Sewatanon, Supaporn Phumiamorn, Kasama Sukapirom, Sansnee Senawong, Surakameth Mahasirimongkol, Zheng Quan Toh, Pinklow Umrod, Thitiporn Somporn, Supaporn Chumpol, Kanokphon Ritthitham, Kulkanya Chokephaibulkit
medRxiv 2021.11.29.21266947; doi: https://doi.org/10.1101/2021.11.29.21266947

Critical success factors for routine immunization performance: A case study of Zambia 2000 to 2018
Katie Rodriguez, Kyra A. Hester, Chama Chanda, Roopa Darwar, Bonheur Dounebaine, Anna S. Ellis, Pinar Keskinocak, Abimbola Leslie, Mwangala Manyando, Maurice Sililo Manyando, Dima Nazzal, Emily Awino Ogutu, Zoe Sakas, Francisco Castillo-Zunino, William Kilembe, Robert A. Bednarczyk, Matthew C. Freeman, the Vaccine Exemplars Research Consortium
medRxiv 2021.11.30.21267060; doi: https://doi.org/10.1101/2021.11.30.21267060

Use of Artificial Intelligence on spatio-temporal data to generate insights during COVID-19 pandemic: A Review
Gihan Jayatilaka, Jameel Hassan, Umar Marikkar, Rumali Perera, Suren Sritharan, Harshana Weligampola, Mevan Ekanayake, Roshan Godaliyadda, Parakrama Ekanayake, Vijitha Herath, G M Dilshan Godaliyadda, Anuruddhika Rathnayake, Samath D. Dharmaratne, Janaka Ekanayake
medRxiv 2020.11.22.20232959; doi: https://doi.org/10.1101/2020.11.22.20232959

Wellcome Open Research [to 4 Dec 2021]
https://wellcomeopenresearch.org/browse/articles
[Accessed 4 Dec 2021]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics Revised
10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity [version 2; peer review: 2 approved with reservations]
John W.G. Addy, Yaw Bediako, Francis M. Ndungu, John Joseph Valetta, Adam J. Reid, Jedida Mwacharo, Joyce Mwongeli Ngoi, Joshua Wambua, Edward Otieno, Jennifer Musyoki, Khadija Said, Matthew Berriman, Kevin Marsh, Philip Bejon, Mario Recker, Jean Langhorne
Peer Reviewers Rodrigo M Corder; Rhea J Longley
Funders: Wellcome Trust; Francis Crick Institute; Medical Research Council
LATEST VERSION PUBLISHED 03 Dec 2021

Data Note metrics Revised
The Avon Longitudinal Study of Parents and Children – A resource for COVID-19 research: Home-based antibody testing results, October 2020. An emphasis on self-screening at a population level [version 2; peer review: 1 approved, 2 approved with reservations]
Kate Northstone, Daniel Smith, Claire Bowring, Amanda Hill, Richard Hobbs, Nicholas Wells, Nicholas J. Timpson
Peer Reviewers Morteza Taheri; Jean-Luc Murk; Citra N.Z. Mattar
Funders: Wellcome Trust; Medical Research Council
LATEST VERSION PUBLISHED 02 Dec 2021

Open Letter metrics Revised
An ethical analysis of vaccinating children against COVID-19: benefits, risks, and issues of global health equity [version 2; peer review: 1 approved, 1 approved with reservations]
Rachel Gur-Arie, Steven R. Kraaijeveld, Euzebiusz Jamrozik
Peer Reviewers Stefan David Baral; Tracy Beth Høeg
Funders: Wellcome Trust; ZonMw
LATEST VERSION PUBLISHED 29 Nov 2021
Abstract
COVID-19 vaccination of children has begun in various high-income countries with regulatory approval and general public support, but largely without careful ethical consideration. This trend is expected to extend to other COVID-19 vaccines and lower ages as clinical trials progress. This paper provides an ethical analysis of COVID-19 vaccination of healthy children. Specifically, we argue that it is currently unclear whether routine COVID-19 vaccination of healthy children is ethically justified in most contexts, given the minimal direct benefit that COVID-19 vaccination provides to children, the potential for rare risks to outweigh these benefits and undermine vaccine confidence, and substantial evidence that COVID-19 vaccination confers adequate protection to risk groups, such as older adults, without the need to vaccinate healthy children. We conclude that child COVID-19 vaccination in wealthy communities before adults in poor communities worldwide is ethically unacceptable and consider how policy deliberations might evolve in light of future developments.

Think Tanks

Think Tanks
 
 
Brookings [to 4 Dec 2021]
http://www.brookings.edu/
Accessed 4 Dec 2021
Africa in Focus
What do Pfizer’s 1996 drug trials in Nigeria teach us about vaccine hesitancy?
Belinda Archibong and Francis Annan
Friday, December 3, 2021

Report
We are not guinea pigs: The effects of negative news on vaccine compliance
Belinda Archibong and Francis Annan
Friday, December 3, 2021
 
 
Center for Global Development [to 4 Dec 2021]
http://www.cgdev.org/page/press-center
Accessed 4 Dec 2021
Africa Should Bargain Hard for COVID Vaccine Equity: Lessons from Indonesia during Avian Flu
December 2, 2021
M any countries around the world have punished most of the African continent for the scientific discovery of the Omicron variant through the imposition of travel bans. These travel bans are more injury upon the injury of low vaccination in Africa. Even well-intentioned rallying phrases such as “vaccine apartheid” or “vaccine equity” still lack the moral weight, indignation, and urgency that we should all feel, no matter which country we live. Words fail us.
Victoria Fan and Steve Kuo

Development Agencies and the “New Normal”
December 1, 2021
In this blog, we map key trends and changes in the development landscape and highlight the implications of these changes for the future of ODA. These findings were presented at the Development Leaders Conference 2021, held earlier this month. All development agencies will need to ask themselves how to better address challenges that extend beyond national boundaries and how to respond to the increasing incidence of poverty and inequality at the national level. Both approaches are linked and can co-exist. But they require a re-think of roles, practices and capacities
Rachael Calleja and Mikaela Gavas

MDB COVID-19 Crisis Response: Where Did the Money Go?
Publication
November 30, 2021
The pandemic and its economic impact have been a revealing test of the multilateral development bank (MDB) system and of individual MDBs. Although lending by the MDBs as a group rose significantly in 2020 (39 percent), this is much less than the rise in MDB lending in response to the Global Financial Crisis (77 percent), despite the much greater economic and social costs of the pandemic.

African Countries Will Continue to Face Tough Choices on COVID-19 Vaccines: We’ve Developed a Toolkit That Can Help
November 29, 2021
African countries will continue to face tough choices on COVID-19 vaccines—we’ve developed a Toolkit that can help.
Tom Drake, Justice Nonvignon and Y-Ling Chi
 
 
Chatham House [to 4 Dec 2021]
https://www.chathamhouse.org/
Accessed 4 Dec 2021
COVID-19: What is needed to address emergent pathogens?
Omicron highlights why a global regime is needed to support countries reporting variants, and that a shared sense of well-being has to come to the fore.
Expert comment
1 December 2021
Dr Osman Dar
Project Director, One Health Project, Global Health Programme

 
 
CSIS
https://www.csis.org/
Accessed 4 Dec 2021
Podcast Episode
Seth Berkley on COVAX’s Past, Present and Future
December 1, 2021 | By Katherine E. Bliss
In this episode, an edited version of a live event on November 15, Katherine talks with Seth Berkley, CEO of Gavi, the Vaccine Alliance, about the first year and a half of COVAX, the global collaboration focused on ensuring globally equitable access to Covid-19 vaccines. One year after the first vaccines were made available, their distribution remains highly unequal, with an overwhelming majority of doses so far delivered to populations in high-income countries. Even as vaccine production has expanded, inequities have worsened, especially among lower-income countries. What difficult lessons have been learned over COVAX’s first year and a half? How likely is it that populations in lower-income countries will have access to Covid-19 vaccines in 2022? And how can countries that have surplus vaccines best support COVAX and the distribution of vaccines globally?

Podcast Episode
Dr. Richard Lessells: Omicron Seen Up Close in South Africa
December 1, 2021 | By J. Stephen Morrison, H. Andrew Schwartz
Dr. Richard Lessells is among the exceptional South African experts on the front lines of discovering and investigating Omicron in South Africa. Alarm bells went off within the scientific community, as it became clear after just a few days that “an extraordinary number of mutations” are clustered in the key regions in the genome for immune protection and transmissibility. It was a “gut feeling. ”…

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 4 Dec 2021
December 2, 2021 News Release
Nearly a Quarter of Vaccinated Adults Received a COVID-19 Booster Shot, Up Sharply from October; Most Other Vaccinated Adults Expect to Get a Booster, Though About 1 in 5 Say They Likely Won’t
Public is Less Optimistic and More Frustrated with State of Vaccinations Now Than in January
Nearly a quarter (23%) of fully vaccinated adults have already received a COVID-19 booster shot, more than double the share who had done so in October (10%), the latest KFF COVID-19 Vaccine Monitor report reveals.…
 
 
ODI [Overseas Development Institute] [to 4 Dec 2021]
https://odi.org/en/publications/
Publications
[No new digest content identified]

Vaccines and Global Health: The Week in Review :: 27 November 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here:

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy